338 related articles for article (PubMed ID: 30523769)
21. Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative topoisomerases I/II inhibitory activities and caspases-mediated apoptosis.
Mohammed HHH; Abbas SH; Hayallah AM; Abuo-Rahma GEA; Mostafa YA
Bioorg Chem; 2021 Jan; 106():104422. PubMed ID: 33248713
[TBL] [Abstract][Full Text] [Related]
22. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
23. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
[TBL] [Abstract][Full Text] [Related]
24. Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: Design, synthesis, biological evaluation and docking studies.
Kadagathur M; Devi GP; Grewal P; Sigalapalli DK; Makhal PN; Banerjee UC; Bathini NB; Tangellamudi ND
Bioorg Chem; 2020 Jun; 99():103629. PubMed ID: 32272367
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
27. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
[TBL] [Abstract][Full Text] [Related]
28. Novel securinine derivatives as topoisomerase I based antitumor agents.
Hou W; Wang ZY; Peng CK; Lin J; Liu X; Chang YQ; Xu J; Jiang RW; Lin H; Sun PH; Chen WM
Eur J Med Chem; 2016 Oct; 122():149-163. PubMed ID: 27344492
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Khadka DB; Park S; Jin Y; Han J; Kwon Y; Cho WJ
Eur J Med Chem; 2018 Jan; 143():200-215. PubMed ID: 29174815
[TBL] [Abstract][Full Text] [Related]
30. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Fukuoka K; Adachi J; Nishio K; Arioka H; Kurokawa H; Fukumoto H; Ishida T; Nomoto T; Yokote H; Tomonari A; Narita N; Yokota J; Saijo N
Jpn J Cancer Res; 1997 Oct; 88(10):1009-16. PubMed ID: 9414664
[TBL] [Abstract][Full Text] [Related]
31. Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin.
Tang Q; Ji F; Wang J; Guo L; Li Y; Bao Y
Eur J Pharm Sci; 2017 Nov; 109():223-232. PubMed ID: 28822757
[TBL] [Abstract][Full Text] [Related]
32. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
Guo W; Miao Z; Sheng C; Yao J; Liu W; Zhu L; Zhang Y; Cheng P; Dong G; Zhuang C; Zhang W
Chem Biodivers; 2011 Jul; 8(7):1266-73. PubMed ID: 21766447
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of new homocamptothecin analogs.
Luo Y; Yu S; Tong L; Huang Q; Lu W; Chen Y
Eur J Med Chem; 2012 Aug; 54():281-6. PubMed ID: 22647222
[TBL] [Abstract][Full Text] [Related]
35. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties.
Lee CC; Chang DM; Huang KF; Chen CL; Chen TC; Lo Y; Guh JH; Huang HS
Bioorg Med Chem; 2013 Nov; 21(22):7125-33. PubMed ID: 24094433
[TBL] [Abstract][Full Text] [Related]
38. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
Morris EJ; Geller HM
J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation.
Zhao CK; Xu L; Wang XH; Bao YJ; Wang Y
Anticancer Agents Med Chem; 2019; 19(4):502-508. PubMed ID: 30663574
[TBL] [Abstract][Full Text] [Related]
40. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer.
Tang H; Zhang Y; Li D; Fu S; Tang M; Wan L; Chen K; Liu Z; Xue L; Peng A; Ye H; Chen L
Eur J Med Chem; 2018 Aug; 156():190-205. PubMed ID: 30006164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
